Trial Profile
Dose-Ranging Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Pegylated Interferon Lambda (BMS-914143) Monotherapy in Interferon-Naive Patients with Chronic Hepatitis B Virus Infection who are HBeAg-positive Revised Protocol 04, incorporating Protocol Amendments 02, 03, 04 and 05
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Peginterferon lambda-1a (Primary) ; Entecavir; Peginterferon alfa-2a
- Indications Hepatitis B
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- Acronyms LIRA-B
- Sponsors Bristol-Myers Squibb
- 28 Dec 2015 Results published in the Journal of Hepatology
- 30 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Apr 2014 Results at 24 weeks post-treatment presented at the 49th Annual Meeting of the European Association for the Study of the Liver.